Introduction
affects Rap1 by inducing the phosphorylation of a serine residue at the C-terminal end of Rap1 (Kawata et al., Rap1A and Rap1B are two members of the Ras family of 1989; Siess et al., 1990) . This phosphorylation induces a small GTPases. Rap1A was first identified both by its translocation of Rap1 from the plasma membrane to the homology to Ras and as the product of a cDNA that cytosol . induces flat revertants of K-ras-transformed cells .
Despite all these results, it is still unclear what the Rap1B is a very close relative of Rap1A, differing in only function of Rap1 is and in which signal transduction nine amino acids predominantly in the C-terminal part of pathway Rap1 is involved. This is partly due to the lack the protein (Noda, 1993) . The functional difference of information on signals that may activate endogenous between the two proteins is unclear and in most studies Rap1, i.e. induce the conversion of the inactive GDPno discrimination between the two has been made. Various bound form of the protein to the active GTP-bound functions of Rap1 have been described, some of which form. Unfortunately, no antibodies are available that can are related to the ability of Rap1 to counteract the function immunoprecipitate Rap1 to measure the ratio of GTP:GDP of Ras. For instance, introduction of the active, GTPbound to Rap1. Therefore, we have developed an alternbound form of Rap1 into fibroblasts inhibits Ras-mediated ative, indirect assay to measure Rap1 activation. This activation of MAP kinase (Cook et al., 1993) . In addition, assay is based on the differential affinity of Rap1GTP constitutively active Rap1 can inhibit Ras-mediated induction of germinal vesicle breakdown in Xenopus oocytes versus Rap1GDP for the Rap binding domain of RalGDS (RBD) as shown by Wittinghofer and co-workers (Herrmann et al., 1996) : whereas the Rap binding domain of RalGDS binds to the GTP-bound form of Rap1 with a very high affinity (K D ϭ10 nM), the affinity for the GDPbound form is undetectably low. Here we report that in platelets α-thrombin stimulation results in a dramatic increase of Rap1 which can associate with RBD in vitro, indicating an increase of Rap1 in the GTP-bound state. We have investigated this activation further and found that most, if not all, activators of platelet function activate Rap1, whereas the negative regulator PGI 2 inhibits Rap1 activation. Furthermore, we show that an increase in the intracellular Ca 2ϩ concentration is both necessary and sufficient to activate Rap1. Finally, we show that Rap1 activation occurs independently of, and probably prior to, platelet aggregation and the association of Rap1 with the cytoskeleton. From these results, we conclude that Rap1 is activated rapidly and strongly by Ca 2ϩ -mediated signalling after platelet stimulation, suggesting a critical role for Rap1 in platelet activation. directed against Rap1. This antibody is specific for Rap1, and does not recognize Ras or R-ras (not shown). A rapid and strong increase in the amount of Rap1 that bound to RBD in vitro was observed ( Figure 1A ). This increase was visible within 5 s after thrombin addition and reached its maximum level at~30 s. At this latter time point, Ͼ50% of total Rap1 could be precipitated with RBD ( Figure 1B ). Since RBD associates exclusively with the GTP-bound form of Rap1 in vitro, with no detectable affinity for the GDP-bound form of Rap1 (Herrmann et al., 1996) , we conclude that α-thrombin induces a rapid conversion of the majority of Rap1 to the GTP-bound, active state.
Platelets were stimulated for 1 and 3 min with α-thrombin (0.1 U/ml), Treatment of platelets with agonists other than TRAP (10 μM), collagen (5 μg/ml), the thromboxane A 2 analogue α-thrombin (Benton et al., 1982; Kroll and Schafer, 1989;  U46619 (1 μM), ADP (10 μM) and PAF (200 nM). Resting platelets Siess, 1989; Inazu et al., 1991) also caused activation of were treated with buffer for 3 min. Rap1 was isolated and identified as indicated in the legend to Figure 1. Rap1; the thrombin receptor-activating peptide (TRAP), collagen, the thromboxane A 2 (TxA 2 ) analogue U46619, ADP and platelet-activating factor (PAF) all induced cesses. Treatment of platelets with indomethacin inhibits TxA 2 formation (Shen and Winter, 1977) ; addition of rapid and strong Rap1 activation (Figure 2 ). Wheat germ agglutinin and lysophosphatidic acid (LPA) treatment also phosphoenolpyruvate and pyruvate kinase (PEP:PK) scavenges ADP, thus inhibiting ADP signalling (Ammit resulted in Rap1 activation (data not shown). From these results, we conclude that Rap1 is activated rapidly and and O 'Neill, 1991; Van Willigen et al., 1996) . Addition of both inhibitors together, at concentrations causing strongly by signalling events common to most, if not all platelet agonists. complete inhibition of both pathways, resulted in only a partial inhibition of Rap1 activation (Figure 3) . From these results, we conclude that although both TxA 2 and Rap1 activation occurs independently of secretion and platelet aggregation ADP do contribute to thrombin-induced activation of Rap1, they are not essential for thrombin to induce Rap1. During thrombin-induced platelet activation, TxA 2 and ADP are released by platelets. Both act in positive feedback Previously, it was shown that Rap1 translocates to the platelet cytoskeleton in a mainly aggregation-dependent loops to enhance further the ongoing platelet activation (Kroll and Schafer, 1989; Siess, 1989) . As TxA 2 and ADP manner (Fischer et al., 1994) . We therefore investigated the effects of disruption of the cytoskeleton and inhibition induce Rap1 activation, we investigated whether thrombininduced Rap1 activation is a consequence of these proof platelet aggregation on thrombin-induced Rap1 activ- Fig. 3 . Rap1 activation occurs independently of both TxA 2 formation and ADP secretion. In the lanes marked 'ϩ inhibitors' platelets were incubated with 30 μM indomethacin for 10 min to inhibit TxA 2 formation. In the last minute, the ADP scavenger system phosphoenolpyruvate:pyruvate kinase (PEP:PK) was added at a final concentration of 0.28 mM PEP and 3 U/ml PK. Subsequently, the platelets were incubated with 0.1 U/ml α-thrombin for the indicated time periods, and Rap1 was isolated and detected as indicated in the legend to Figure 1 . Control platelets (-inhibitors) were treated with 0.1 U/ml α-thrombin, only.
ation. Treatment of platelets with cytochalasin D prevents activation-dependent actin polymerization and remodelling of the cytoskeleton (Dash et al., 1995) . This treatment totally prevented the translocation of Rap1 to the cytoskeleton ( Figure 4A ). Cytochalasin D, however, did not affect thrombin-induced activation of Rap1 ( Figure 4B ), showing that Rap1 activation occurs independently of translocation to the cytoskeleton. Furthermore, in platelets that were not allowed to aggregate by the addition of the RGDS peptide, which blocks integrin function (Hynes, 1992; Calvete, 1994) , Rap1 activation was not impaired ( Figure 5 ). Also, inhibition of aggregation by not stirring the platelet suspension did not affect α-thrombin-induced activation of Rap1 (data not shown). From these results, we conclude that Rap1 activation occurs independently of Rap1 translocation to the cytoskeleton and of platelet aggregation.
Increase in intracellular Ca 2⍣ is necessary and methods. Amounts of protein representing 3ϫ10 7 platelets were used from intracellular stores (Kroll and Schafer, 1989; Siess, for protein immunoblot analysis with a monoclonal antibody directed 1989). Figure 6A demonstrates that inhibition of PLC by against Rap1. (B) Rap1 was precipitated with RBD and analysed as U73122 (Okamoto et al., 1995) strongly reduced thrombinindicated in the legend of Figure 1 . The band present above Rap1 is caused by aspecific binding to the Ni 2ϩ -NTA-agarose beads.
induced activation of Rap1, suggesting that either PKC or Ca 2ϩ is an important factor in Rap1 regulation. We therefore tested whether an increase in the intracellular of TxA 2 or secretion of ADP, since inhibitors of both signalling events, indomethacin and PEP:PK, caused only Ca 2ϩ concentration is important for the activation of Rap1. Inhibition of the cytosolic Ca 2ϩ increase by chelation of a slight reduction of Ca 2ϩ -induced Rap1 activation ( Figure  6A ). Moreover, this reduction is probably due to the intracellular Ca 2ϩ with BAPTA-AM (Watson et al., 1995) completely blocked activation of Rap1 by α-thrombin. On slightly lower Ca 2ϩ level induced by thapsigargin and ionomycin in the presence of indomethacin and PEP:PK the other hand, increasing the concentration of intracellular Ca 2ϩ with ionomycin  (data not shown). Inhibition of PKC by several inhibitors, i.e. staurosporin, Doni et al., 1994) or thapsigargin (Authi et al., 1993; strongly activated Rap1 ( Figure  bisindolylmaleimid and calphostin C (Tamaoki, 1991; Toullec et al., 1991) , did not at all or only marginally 6A). This indicates that an increased level of Ca 2ϩ is both necessary and sufficient to activate Rap1. The Ca 2ϩ effect affect the activation of Rap1 by α-thrombin ( Figure 6B ). Consistent with this, activation of PKC by the phorbol is not due simply to Ca 2ϩ -induced production and release ester phorbol 12-myristate 13-acetate (PMA) (Kroll and Schafer, 1989; Siess, 1989 ) activated Rap1 only slightly and after a prolonged period of time ( Figure 6B ). From these results, we conclude that Rap1 activation is mediated by an increase in intracellular Ca 2ϩ , which is both necessary and sufficient, whereas activation of PKC does not play an essential role.
Prostaglandin I 2 (PG I 2 ) inhibits thrombin-and Ca 2⍣ -induced Rap1 activation PGI 2 , a potent inducer of cAMP production, is a strong antagonist of platelet activation (Kroll and Schafer, 1989; Siess, 1989) . We therefore tested the effect of PGI 2 on thrombin-induced activation of Rap1. Figure 7A shows substrate for cAMP-dependent protein kinase A (PKA) Rap1 was precipitated with RBD and analysed as indicated in the (Kawata et al., 1989; Siess et al., 1990) . This phosphoryllegend to Figure 1. ation, which results in a lower electrophoretic mobility of Rap1 (Siess et al., 1990; Siess and Grünberg, 1993) , occurs only slowly and was still very limited 2 min after Grünberg et al., 1995) . Under these conditions, thrombin activated the phosphorylated, shifted form of Rap1 ( Figure  PGI 2 treatment of the platelets ( Figure 8A ; Grünberg et al., 1995) . At this time point, however, PGI 2 had already 8B). We conclude, therefore, that the PGI 2 -induced inhibition of Rap1 activation is not caused by phosphorylation completely inhibited Rap1 activity (see Figure 7A ). Furthermore, α-thrombin was able to activate phosphorylated of the GTPase. Rap1 apparently normally. This was shown by pre-treating platelets with PGI 2 for various times, followed by thrombin Discussion stimulation: whereas platelets became fully responsive to thrombin stimulation within 60 min after PGI 2 addition
We have developed a novel assay to identify the active GTP-bound state of Rap1. This assay is based on the (due to the instability of PGI 2 ), Rap1 phosphorylation remained high ( Figure 8A ; Siess and Grünberg, 1993;  observation that the GTP-bound form of Rap1 associates with the RBD of RalGDS with high affinity in vitro, with polyhistidine-tagged RBD bound to Ni 2ϩ -NTAagarose beads, we observed a large amount of Rap1 whereas no interaction can be detected with the GDPbound form of Rap1. When we incubated cell lysates of associated with RBD only in stimulated platelets. Based on the in vitro binding affinity, we conclude that this resting and α-thrombin-stimulated human blood platelets increase is due to an induction of the GTP-bound form of Rap1 by α-thrombin. Alternatively, Rap1 might be constitutively GTP-bound but complexed to a factor in resting platelets that prevents it from associating with RBD. Stimulation with thrombin would then lead to dissociation of this factor, rendering Rap1 available for RBD binding. To discriminate between the two possibilities, the ratio of GDP and GTP bound to Rap1 in platelets needs to be measured. Unfortunately, suitable antisera for Rap1 immunoprecipitation, which are essential for such an experiment, are still not available. Irrespective of this, in functional terms there may be no difference between the two mechanisms, as both result in free GTPbound, active Rap1. The assay was used to monitor the activation of Rap1 in platelets. We observed that all agonists tested that activate platelets also activate Rap1. This could imply that Rap1 is either involved in a signalling pathway common to all of these agonists or that Rap1 activation is a secondary event, induced by positive feedback loops (TxA 2 release and ADP secretion) or by platelet aggregation, for instance. However, inhibition of both TxA 2 production and ADP signalling as well as aggregation did not affect α-thrombin-induced activation of Rap1 significantly. This strongly suggests that Rap1 activation is one of the early events in platelet activation. The observed translocation of Rap1 to the cytoskeleton is not involved in the activation of Rap1, since it occurs much later than Rap1 activation. Furthermore, inhibition of actin polymerization by cytochalasin D, which totally blocked Rap1 association with the cytoskeleton, did not inhibit Rap1 activation. Therefore, we conclude that Rap1 is involved in a signalling pathway common to all agonists tested. A common denominator for all these agonists is the increase in intracellular Ca 2ϩ by mobilization of Ca 2ϩ from internal stores and by influx of extracellular Ca 2ϩ . Indeed, we found that increasing the concentration of intracellular Ca 2ϩ with either ionomycin or thapsigargin induced Rap1 Fig. 7 . Effects of PGI 2 treatment of platelets on Rap1 activation and cytosolic Ca 2ϩ levels. (A) PGI 2 pre-treatment prevents Rap1 activation by α-thrombin. Platelets were treated with thrombin (α-T, 0.1 U/ml), in the presence or absence of PGI 2 added 2 min earlier at 10 ng/ml. Rap1 was precipitated with RBD and analysed as indicated in the legend to Figure 1. (B) PGI 2 treatment of α-thrombin-activated platelets results in a time-dependent reduction of Rap1 activity. Platelets were treated with α-thrombin (0.1 U/ml) for 15 s to activate Rap1. PGI 2 (10 ng/ml) was then added for the indicated times. Controls were either left untreated or were activated with α-thrombin for 120 s to serve as a positive control for the activity state of Rap1 at the end of the experiment. Rap1 was precipitated with RBD and analysed as indicated in the legend to Figure 1 . (C) PGI 2 reverses the α-thrombin-induced rise in the cytosolic Ca 2ϩ level. The intracellular Ca 2ϩ level was monitored in Fura-2-loaded platelets as described in Materials and methods. α-Thrombin (0.1 U/ml) was added at the indicated time point (α-T), 15 s later PGI 2 (10 ng/ml) was added (indicated with PGI 2 ) and incubation was continued for another 90 s. (D) PGI 2 pre-treatment of platelets prevents Rap1 activation by the cytosolic Ca 2ϩ -elevating agents thapsigargin and ionomycin. Platelets were incubated either with or without PGI 2 (10 ng/ml) for 2 min. Subsequently, either ionomycin (100 nM) ϩ CaCl 2 (1 mM) or thapsigargin (100 nM) was added for 1 min. Rap1 was precipitated with RBD and analysed as indicated in the legend to Figure 1. candidate for mediating the PGI 2 inhibition is Rap1GAP. Phosphorylation of this protein is induced by elevated levels of cAMP, at least in insect cells and the SK-MEL-3 cell line Rubinfeld et al., 1992) . Whether this occurs in platelets and whether it affects GAP activity is still unknown. It should be noted that phosphorylation of Rap1 correlates with the PGI 2 -induced translocation of Rap1 from the plasma membrane to the cytosol . This translocation may be another form of inactivation by PGI 2 , which clearly interferes at a different level of Rap1-mediated signalling.
From the rapid activation of a major fraction of Rap1 and the stringent control of Rap1 activity by PGI 2 , we anticipate that Rap1 plays a critical role in agonistinduced, calcium-mediated events in platelet activation. Interestingly, Ca 2ϩ -induced signalling is involved in the activation of integrin αIIbβ3, resulting in the exposure of binding sites for fibrinogen and, subsequently, platelet aggregation (Kroll and Schafer, 1989; Siess, 1989) . It is tempting, therefore, to speculate that Rap1 is involved in this process. Support for this possibility comes from the (Zhang et al., 1996) . A function of Rap1 in the activation 
Materials and methods
the indicated time periods. Subsequently, thrombin was added and the incubation was continued for another minute, followed by cell lysis Production of his-tagged RalGDS-RBD (ϩα-T). As a control, platelets incubated with PGI 2 were not
The cDNA encoding the 97 amino acids spanning RBD was isolated incubated with thrombin (-α-T). Rap1 was precipitated with RBD and from pGEX-RGF97 (Herrmann et al., 1996) as a BamHI-XhoI fragment. analysed as indicated in the legend to Figure 1 . Rap1-P indicates the
The BamHI site was blunted with Klenow DNA polymerase. Subslower migrating, phosphorylated form of Rap1. It should be noted sequently, the fragment was inserted into the pET-15b vector (Novagen) that due to the instability of PGI 2 its inhibitory effect on Rap1 digested with NdeI (and blunted with Klenow DNA polymerase) and activation by α-thrombin is only seen 2 min after PGI 2 addition to the XhoI. The construct was transformed into Escherichia coli (strain platelets. At all later time points, PGI 2 has been broken down and BL21). Protein production was initiated by addition of isopropyl β-Dplatelets have restored responsiveness to α-thrombin (Siess and thiogalactopyranoside (IPTG) to the culture. The fusion protein was Lapetina, 1990; Siess and Grünberg, 1993) . affinity purified on a Ni 2ϩ -NTA-agarose column (Qiagen) from the supernatant of bacteria lysed by sonication and freeze-thaw cycles in a sucrose-containing buffer.
activation. In addition, BAPTA-AM, which chelates (PRP). Then, 0.1 vol. of ACD (2.5% trisodium citrate, 1.5% citric PGI 2 , which activates adenylate cyclase to increase the acid, 2% D-glucose) was added to the PRP to lower the pH of the levels of cAMP in platelets, inhibits thrombin-induced plasma to 6.5 and thus prevent platelet activation during further activation of Rap1. This is in agreement with the observisolation. Platelets were purified from PRP by centrifugation at 700 ation that PGI 2 inhibited thrombin-induced increases in g for 15 min at room temperature. The platelet pellet was resuspended in HEPES/Tyrode buffer (10 mM HEPES, 137 mM NaCl, 2.68 mM intracellular Ca 2ϩ . However, thapsigargin-or ionomycin-
